Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial Infarction

Abstract

REATMENT OF LEAD TOXICITYwith chelation was first reported with EDTA in the early 1950s. 1 Apparent success in reducing metastatic calcium deposits 2 led Clarke et al 3 in 1956 to treat angina patients with EDTA, and others to use chelation for various forms of atherosclerotic disease. [4][5][6] Chelation therapy evolved to constitute infusions of vitamins and disodium EDTA, a drug that binds divalent and some trivalent cations, including calcium, magnesium, lead, cadmium, zinc, iron, aluminum, and copper, facilitating their urinary excretion. 7,8 Over the next decades, based on favorable anecdotal and case report experience, chelation practitioners increased their use of EDTA for coronary and peripheral artery disease. The 2007 National Health Statistics Report compared chelation use since 2002 and noted Author Affiliations are listed at the end of this article.

A Novel Chemical Solution to Demineralize Valvular and Coronary Calcification: Insights from Yogurt and Honey

“…A meta-analysis of several studies that involved the use of statins in patients with aortic stenosis failed to show any improvement in outcome or delay in progression of the severity of aortic stenosis [36]. Recently, the use of disodium-EDTA chelation therapy in patients with coronary artery disease and prior myocardial infarction showed less coronary revascularization in the chelation arm (15%) compared to placebo (18%); HR, 0.81 (95% CI, 0.64-1.02); however, the study received major critique and the findings were not sufficient to support the routine use of chelation therapy as secondary prevention for such patients [37]. Our findings may pave the way for further clinical research to determine if the LAGA solution is effective in Score 1= absent calcification.…”

Current Approach to the Chronic Ischemic Heart Disease in the Light of the Current Diagnosis and Assessment Guidelines

“…Daha önceden Mİ öyküsü olan hastalarda şelasyon tedavisi ile plaseboyu karşılaştıran randomize kontrollü Tactical Aviation Control Team (TACT) çalışmasında total mortalite, rekürren Mİ, inme, koroner revaskülarizasyon veya angina nedeniyle hospitalizasyondan oluşan primer sonlanım noktasında ılımlı şekilde faydalı bulunmuş. Bununla beraber hastaların bir kısmının takip süresince hayatını kaybetmesi ve tedavinin bilimsel dayanağının yeterli olmaması nedeniyle çalışmanın yazarları rutin olarak bu tedavinin uygulanmasını önermemişlerdir (73). Ayrıca EDTA'nın hızlı bir şekilde uygulanması hipokalsemi, böbrek yetersizliği ve ölümle sonuçlanabilmektedir.…”

Are Concerns About Reliability in the Trial to Assess Chelation Therapy Fair Grounds for a Hasty Dismissal?

“…3 The investigators used an expanded definition of diabetes mellitus compared with what was prespecified in trial design 1 or reported previously. 2 As a result, the size of the cohort increased from 538 to 633, and the number of primary end point events accrued increased from 169 to 197. The principal finding is that chelation therapy was associated with a reduction in the primary MACE plus and secondary stringent MACE end pointa composite of death, nonfatal myocardial infarction, or stroke.…”

“…This is understandable because trials are seldom designed adequately to assess treatment effects across multiple end points within subgroups. Had the investigators adjusted for 3 additional subgroups that were not prespecified but presented in the original trial report (high-dose vitamins, CAM sites, prior revascularization), 2 the primary end point would still be significant at the adjusted P-value threshold of 0.003 (0.036/12=0.003) as would treatment by diabetes mellitus interaction: adjusted P for interaction=0.043 (adjusted P=1− [1−unadjusted P] k , where k is the number of subgroups). Nonetheless, the number of subgroups explored is arguably large for a trial this size, compounding the challenge of nonreplication in future trials.…”